Answers are grounded in this paper and cite their sources.
BACKGROUND: Performance of the uCGM 100 continuous glucose monitoring (CGM) system, featuring a 15.5-day, real-time, and factory-calibrated glucose sensor, is evaluated against venous plasma reference for adult participants (≥18 years) in a multicenter, prospective clinical study. METHODS: A total number of 60 participants were enrolled at three clinical sites in China, and each participant wore sensors on the back of each upper arm for 15.5 days. Three in-clinic visits, lasting eight hours during each visit, were conducted by each participant to perform multiple venous plasma glucose measurements using Biosen C-Line GP+ (EKF Diagnostics) Glucose/Lactate Measuring System. Venous plasma blood glucose sample tests covered the start, middle, and end wear of the sensor (day 1, days 3-5, days 7-9, days 11-13, or the last 24 hours). Analytic performance included accuracy such as ±20% or ±20 mg/dL (%20/20) agreement rate with reference values, and mean absolute relative difference (MARD) between CGM and reference values. RESULTS: A total of 11 576 matched data pairs (120 sensors) were analyzed. The overall MARD and %20/20 agreement rate for the CGM system was 7.6% and 95.5%, respectively, compared with venous blood reference. The %20/20 agreement remained consistently above 93% across wear days and glucose ranges. No serious adverse events were recorded. Usability survey showed 99.8% positive feedback, demonstrating good usability. CONCLUSIONS: The novel CGM system was proven to provide accurate and reliable glucose readings in adults with diabetes.
No takes yet. Share an insight, caveat, or question.
Zhao et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: